We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05170828
Recruitment Status : Not yet recruiting
First Posted : December 28, 2021
Last Update Posted : December 28, 2021
Sponsor:
Collaborator:
Center for International Blood and Marrow Transplant Research
Information provided by (Responsible Party):
Ossium Health, Inc.

Brief Summary:
Multicenter single arm study to assess the safety and efficacy of allogeneic transplantation using cryopreserved bone marrow from deceased MMUD and PTCy, sirolimus and MMF for GVHD prophylaxis.

Condition or disease Intervention/treatment Phase
Acute Leukemia Myelodysplastic Syndromes T-lymphoblastic Lymphoma Acute Lymphocytic Leukemia Acute Myeloid Leukemia Acute Biphenotypic Leukemia Acute Undifferentiated Leukemia Drug: Cyclophosphamide Drug: Fludarabine Radiation: Total Body Irradiation Drug: Busulfan Drug: Mesna Drug: Sirolimus Drug: Mycophenolate Mofetil Drug: Filgrastim Procedure: Bone Marrow Transplant Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: PRESERVE: A Multi-Center Trial Using Banked, Cryopreserved HLA-Mismatched Unrelated Donor Bone Marrow and Post-Transplantation Cyclophosphamide in Allogeneic Transplantation for Patients With Hematologic Malignancies
Estimated Study Start Date : March 2022
Estimated Primary Completion Date : March 2024
Estimated Study Completion Date : November 2024


Arm Intervention/treatment
Regmin A (RIC)
Pre-transplant conditioning treatment with Fludarabine, Cyclophosphamide, and Total Body Irradiation (TBI)
Drug: Cyclophosphamide
pre-transplant conditioning treatment
Other Name: Cytoxan

Drug: Fludarabine
pre-transplant conditioning treatment
Other Name: Fludara

Radiation: Total Body Irradiation
pre-transplant conditioning treatment
Other Name: TBI

Drug: Mesna
given with cyclophosphamide
Other Name: Mesnex

Drug: Sirolimus
post-transplant treatment for GVHD

Drug: Mycophenolate Mofetil
post-transplant treatment for GVHD
Other Name: MMF

Drug: Filgrastim
post-transplant treatment for GVHD
Other Name: G-CSF

Drug: Cyclophosphamide
post-transplant treatment for GVHD
Other Name: Cytoxan

Procedure: Bone Marrow Transplant
Transplant with investigational bone marrow product
Other Name: Hematopoietic Stem Cell Transplant

Regimen B (FIC)
Pre-transplant conditioning treatment with Busulfan and Cyclophosphamide OR Fludarabine
Drug: Cyclophosphamide
pre-transplant conditioning treatment
Other Name: Cytoxan

Drug: Fludarabine
pre-transplant conditioning treatment
Other Name: Fludara

Drug: Busulfan
pre-transplant conditioning treatment
Other Name: Busulfelx

Drug: Mesna
given with cyclophosphamide
Other Name: Mesnex

Drug: Sirolimus
post-transplant treatment for GVHD

Drug: Mycophenolate Mofetil
post-transplant treatment for GVHD
Other Name: MMF

Drug: Filgrastim
post-transplant treatment for GVHD
Other Name: G-CSF

Drug: Cyclophosphamide
post-transplant treatment for GVHD
Other Name: Cytoxan

Procedure: Bone Marrow Transplant
Transplant with investigational bone marrow product
Other Name: Hematopoietic Stem Cell Transplant

Regimen C (FIC)
Pre-transplant conditioning treatment with Cyclophosphamide and Total Body Irradiation (TBI)
Drug: Cyclophosphamide
pre-transplant conditioning treatment
Other Name: Cytoxan

Radiation: Total Body Irradiation
pre-transplant conditioning treatment
Other Name: TBI

Drug: Mesna
given with cyclophosphamide
Other Name: Mesnex

Drug: Sirolimus
post-transplant treatment for GVHD

Drug: Mycophenolate Mofetil
post-transplant treatment for GVHD
Other Name: MMF

Drug: Filgrastim
post-transplant treatment for GVHD
Other Name: G-CSF

Drug: Cyclophosphamide
post-transplant treatment for GVHD
Other Name: Cytoxan

Procedure: Bone Marrow Transplant
Transplant with investigational bone marrow product
Other Name: Hematopoietic Stem Cell Transplant




Primary Outcome Measures :
  1. Neutrophil engraftment [ Time Frame: Day 35 Post HCT ]
    Run-in safety phase primary endpoint; Neutrophil engraftment is defined as neutrophil recovery by Day 35. Neutrophil recovery is defined as donor-derived absolute neutrophil count (ANC) ≥ 500/mm3 for three consecutive days with evidence of donor chimerism in bone marrow or peripheral blood. Full donor chimerism is >95%, and mixed donor chimerism is defined as 5-95%.

  2. Cumulative incidence and kinetics of neutrophil and platelet recovery [ Time Frame: Day 35 Post HCT ]
    Main phase primary endpoint; Neutrophil recovery is defined as achieving an absolute neutrophil count (ANC) greater than or equal to 500/mm3 for three consecutive measurements on three different days. The first of the three days will be designated the day of neutrophil recovery. The competing event is death without neutrophil recovery. For subjects who never drop ANC below 500/mm3, the date of neutrophil recovery will be Day 1 post-transplant. Platelet recovery is defined by two different metrics: the first day of a sustained platelet count greater than or equal to 20,000/mm3 or greater than or equal to 50,000/mm3 with no platelet transfusions in the preceding seven days. The first day of sustained platelet count above these thresholds will be designated the day of platelet engraftment. For subjects who never drop their platelet count below 20,000/mm3, the date of platelet recovery will be Day 1 post HCT.

  3. Overall survival (OS) [ Time Frame: 1-year Post HCT ]
    Main phase primary endpoint; The primary endpoint for the study is OS at 1-year post-HCT. The event is death from any cause. The time to this event is the time from HCT to death, loss to follow-up, or end of study (whichever comes first). Subjects who are lost to follow-up prior to 1-year will be censored at the time of the last observation, and the OS probability will be estimated using the Kaplan-Meier method.


Secondary Outcome Measures :
  1. Cumulative incidences of aGVHD and cGVHD [ Time Frame: 1-year Post HCT ]
    aGVHD is defined as any skin, gastrointestinal or liver abnormalities fulfilling the criteria of grades II-IV or grades III-IV. cGVHD is defined per National Institutes of Health (NIH) Consensus Criteria and includes organ involvement and severity, and overall global composite score (mild/moderate/severe).

  2. Transplant-related mortality (TRM) [ Time Frame: Day 100 and 1-year Post HCT ]
    TRM is defined as death without evidence of disease progression or recurrence. TRM will be evaluated at Day 100, 180, and 1-year (Day 365).

  3. NK, B- and T-cell immune reconstitution [ Time Frame: Days 35, 100, 180, and 1-year Post HCT ]
    Quantitative assessments of peripheral blood CD3, CD4, CD8, CD19 positive lymphocytes will be done through flow cytometric analysis at Days 35, 100, 180, and 365 post-HCT. Qualitative assessments will be tabulated according to time from transplant.

  4. Progression free survival (PFS) [ Time Frame: 1-year Post HCT ]
    Progression free survival will be estimated at 1-year (Day 365) post-transplant. An event for this time to event outcome is defined as disease relapse or progression, or death by any cause.

  5. Event free survival (EFS) [ Time Frame: 1-year Post HCT ]
    EFS will be estimated at 12 months post-HCT. An event for this time to event outcome includes graft failure (PGF by Day 35 or secondary graft failure), relapse or progression of underlying disease, death, grade III-IV acute GVHD, or NIH-severe chronic GVHD.

  6. GVHD relapse free survival (GRFS) [ Time Frame: 1-year Post HCT ]
    GRFS will be estimated at 1-year (Day 365) post-transplant. An event for this time to event outcome is defined as relapse or progression of underling disease, graft failure, grade III-IV acute GVHD, chronic GVHD requiring systemic immune suppression, or death by any cause.

  7. Cumulative incidence of cytokine release syndrome (CRS) [ Time Frame: Day 14 Post HCT ]
    Overall incidence of CRS of any grade and grade 3 or 4 CRS post-transplant will be reported on all patients. CRS will be defined and graded using the American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading criteria.

  8. Donor chimerism [ Time Frame: Days 35, 56, 100, 180, and 1-year Post HCT ]
    Peripheral blood chimerism (% of donor chimerism) in whole blood (unsorted) will be described on Day 35, 56, 100, 180, and 1-year (Day 365). Donor cell engraftment will be assessed with donor/recipient chimerism studies at Day 100. Chimerism may be assessed in CD3 blood cell fraction. For the purpose of this protocol, mixed chimerism is defined as the presence of donor cells, as a proportion of total cells to be less than 95% but at least 5% in the bone marrow or peripheral blood. Full donor chimerism is defined as greater than or equal to 95% of donor cells. Mixed and full chimerism will be evidence of donor cell engraftment. Donor cells of less than 5% by Day 35 will be considered as graft rejection. The proportion of patients with each level of chimerism described above will be described as part of this outcome. For sorted blood cell fractions, CD3+ donor cell chimerism will be used to define the donor/recipient chimerism status.

  9. Cumulative incidences of viral reactivations and infections [ Time Frame: Days 100, 180, and 1-year Post HCT ]
    The incidence of Cytomegalovirus (CMV), Epstein-Barr virus (EBV), BK virus, Adenovirus (ADV), and Human herpesvirus (HHV-6) viral activations and infections at Days 100, 180 and 1-year (Day 365).

  10. Cumulative incidence of primary disease relapse/progression [ Time Frame: 1-year Post HCT ]
    Testing for recurrent malignancy in the blood, bone marrow or other sites will be used to assess relapse and progression post-HCT. For the purpose of this study, relapse is defined by either morphological, cytogenetic/molecular or radiological evidence of disease consistent with pre-HCT features, in line with institutional standards. The event for this endpoint is the time interval from HCT to relapse/recurrence of disease or to last follow-up through 1-year (Day 365) post-HCT. Death in remission is considered a competing risk.


Other Outcome Measures:
  1. Length of stay in hospital [ Time Frame: Day 100 Post HCT ]
    Cumulative days alive and out of the hospital in the first 100 days and in the first year post-transplant.

  2. Incidence of clinically-significant infections [ Time Frame: 1-year Post HCT ]
    A clinically significant infection is defined as an infection that requires therapeutic intervention.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged ≥ 18 and < 71 years (Note: HIV-negative subjects with MDS must be aged <50 at the time of signing the informed consent form)
  • Diagnosed with
  • Acute leukemias or T-lymphoblastic lymphoma (T-LBL) in 1st or subsequent CR
  • Acute lymphocytic leukemia (ALL) or T-LBL as defined by the following:
  • < 5% blasts in the bone marrow
  • Normal maturation of all cellular components in the bone marrow
  • No currently active extramedullary disease (EMD) (e.g., central nervous system (CNS), soft tissue disease)
  • ANC ≥ 1,000/mm3
  • Acute myeloid leukemia (AML) defined by the following:
  • < 5% blasts in the bone marrow
  • No blasts with Auer rods
  • Normal maturation of all cellular components in the bone marrow
  • No currently active EMD (e.g., CNS, soft tissue disease)
  • ANC ≥ 1,000/mm3
  • Acute biphenotypic leukemia (ABL)/Acute undifferentiated leukemia (AUL) defined by the following:
  • < 5% blasts in the bone marrow
  • Normal maturation of all cellular components in the bone marrow
  • No currently active EMD (e.g., CNS, soft tissue disease)
  • ANC ≥ 1,000/mm3
  • Myleodysplastic Syndromes (MDS), fulfilling the following criteria:
  • Subjects with de novo MDS who have or have previously had Intermediate-2 or High-risk disease as determined by the IPSS. Current Intermediate-2 or High- risk disease is not a requirement
  • Subjects must have < 20% bone marrow blasts, assessed within 60 days of informed consent
  • Subjects may have received prior therapy for the treatment of MDS prior to enrollment
  • Performance status: Karnofsky ≥ 60%
  • Adequate organ function defined as:
  • Cardiac: LVEF at rest ≥ 35% (RIC cohort) or LVEF at rest ≥ 40% (FIC cohort), or LVFS ≥ 25%
  • Pulmonary: DLCO, FEV1, FVC ≥ 50% predicted by pulmonary function tests (PFTs). DLCO value may be corrected or uncorrected for hemoglobin
  • Hepatic: total bilirubin ≤ 2.5 mg/dL, and ALT, AST, and ALP < 5 x ULN (unless ALT, AST, and/or ALP are disease related)
  • Renal: SCr within normal range for age (see table 5.1B). If SCr is outside normal range for age, CrCl > 40 mL/min/1.73m2 must be obtained (measured by 24-hour (hr) urine specimen or nuclear glomerular filtration rate (GFR), or calculated GFR (by Cockcroft-Gault formula)
  • Subjects must have the ability to give informed consent according to applicable regulatory and local institutional requirements
  • Availability of deceased HLA MMUD cryopreserved product through Ossium cryobank
  • HLA MMUD defined as 4-7/8 HLA-allele matching at MHC class (A, B, or C) or MHC class II (DRB1)
  • Additional MHC class II HLA (DP and DQ) typing will be collected, but not incorporated in donor selection

Exclusion Criteria:

  • Pediatric patients (17 years or younger)
  • Suitable HLA-matched related or 8/8 allele matched (HLA-A, -B, -C, -DRB1) unrelated donor excluding Ossium product
  • Autologous HCT < 3 months prior to the time of signing the informed consent form
  • Pregnancy or lactation
  • Treatment with an investigational drug or other interventional GVHD clinical trials
  • Current uncontrolled bacterial, viral or fungal infection (currently taking medication with evidence of progression of clinical symptoms or radiologic findings)
  • Prior allogeneic HCT
  • Primary myelofibrosis or myelofibrosis secondary to essential thrombocythemia or polycythemia vera
  • Subjects with MDS may not receive RIC and must be < 50 years of age at the time of signing the informed consent form
  • Any condition(s) or diagnosis, both physical or psychological, or physical exam finding that in the investigator's opinion precludes participation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05170828


Contacts
Layout table for location contacts
Contact: Shannon Clark, MS 6124025362 sclark2@nmdp.org

Sponsors and Collaborators
Ossium Health, Inc.
Center for International Blood and Marrow Transplant Research
Investigators
Layout table for investigator information
Study Chair: Jeffery Auletta, MD Center for International Blood and Marrow Transplant Research
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Ossium Health, Inc.
ClinicalTrials.gov Identifier: NCT05170828    
Obsolete Identifiers: NCT05068401
Other Study ID Numbers: PRESERVE
First Posted: December 28, 2021    Key Record Dates
Last Update Posted: December 28, 2021
Last Verified: December 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Ossium Health, Inc.:
Leukemia
MDS
T-LBL
ALL
AML
ABL
AUL
Bone marrow transplant
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Hematologic Neoplasms
Leukemia, Biphenotypic, Acute
Myelodysplastic Syndromes
Neoplasms by Histologic Type
Neoplasms
Bone Marrow Diseases
Hematologic Diseases
Leukemia, Lymphoid
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Neoplasms by Site
Mycophenolic Acid
Sirolimus
Cyclophosphamide
Busulfan
Fludarabine
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antibiotics, Antineoplastic